Evaluation of novel particles as an inhalation system for GLP‐1

Abstract

These data demonstrate the feasibility of administering native GLP-1 as GLP-1 Technosphere Inhalation Powder for diabetes therapy.

Aerosolized GLP-1 for Treatment of Diabetes Mellitus and Irritable Bowel Syndrome

“…Histological analyses demonstrated an increase of insulin-secreting cells per islet in the GLP-1 treated group vs. the controls (51.5 AE 10.1 % vs. 42.1 + 8.4 %) whereas β-cell mass and apoptosis showed no differences suggesting that the reduced concentrations in plasma glucose observed in the intraperitoneal glucose tolerance test result from insulin induction but not alteration in proliferation or apoptosis. Taken together, the results suggest the feasibility of GLP-1 inhalative administration by means of the Technosphere ® platform in rats(Leone-Bay et al 2009) (Table 1).…”

“…The feasibility of inhalation of native GLP-1 by means of the Technosphere ® platform was demonstrated in rats by Leone-Bay et al (2009). These authors prepared GLP-1 Technosphere ® powders containing 5 %, 10 % and 15 % GLP-1.…”

Stability and efficacy of synthetic cationic antimicrobial peptides nebulized using high frequency acoustic waves

“…8 Thus, pulmonary delivery of peptides via inhalation using dry powder inhalers (DPIs) is being extensively explored for the treatment of both pulmonary and non-pulmonary diseases. [9][10][11][12][13] In addition, aerosolized AMPs are currently being incorporated into treatment regimens as a conjunctive therapy in patients with multi-drug resistant infection who are irresponsive to systemic therapy. 14 a) Authors to whom correspondence should be addressed.…”

“…15 For peptide delivery using dry powder inhalers, special excipients and pre-processing, such as micronization, are required to generate discrete particles for better flow characteristics and homogeneous distribution of peptides within the powder blend. 11,16 Conventional nebulizers, however, are limited by their large power requirements and sizes, which hinder portable use outside hospital settings, the tendency of their orifices to clog, and their propensity to denature macromolecules, such as the peptides considered in this work. 17 Emerging from recent developments in SAW microfluidics, [18][19][20][21][22] SAW nebulizers 23,24 have been identified as a promising low cost alternative for conventional nebulizers, 25 in addition to other novel applications such as mass spectrometry (MS), [26][27][28] among others.…”

Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

“…It is composed of a tandem repeat of two copies of recombinant human GLP-1(7-36) (blue and green helices) genetically fused to the N terminus of human albumin (in magenta) (Matthews et al, 2008). An alanine3glycine substitution in position 8 of both GLP-1 monomers (Cassidy et al, 2008;Leone-Bay et al, 2009), a GLP-1(7-36)amide absorbed onto Technosphere microparticles, can be used for inhalation.…”